| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 12 | 2022 | 690 | 2.490 |
Why?
|
| Drainage | 9 | 2021 | 416 | 2.130 |
Why?
|
| Pancreatic Fistula | 5 | 2021 | 99 | 1.760 |
Why?
|
| Postoperative Care | 4 | 2019 | 739 | 1.320 |
Why?
|
| Pancreatic Neoplasms | 22 | 2023 | 5061 | 1.220 |
Why?
|
| Carcinoma, Pancreatic Ductal | 12 | 2023 | 1724 | 1.040 |
Why?
|
| Postoperative Complications | 11 | 2021 | 5542 | 0.990 |
Why?
|
| Pancreatectomy | 10 | 2023 | 652 | 0.920 |
Why?
|
| Pancreas | 4 | 2023 | 718 | 0.780 |
Why?
|
| Choristoma | 1 | 2018 | 85 | 0.650 |
Why?
|
| Pancreatic Diseases | 1 | 2018 | 108 | 0.630 |
Why?
|
| Incidental Findings | 1 | 2018 | 272 | 0.590 |
Why?
|
| Nutritional Support | 1 | 2017 | 80 | 0.570 |
Why?
|
| Spleen | 1 | 2018 | 676 | 0.570 |
Why?
|
| Clinical Protocols | 1 | 2018 | 467 | 0.560 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 130 | 0.530 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2009 | 196 | 0.400 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2008 | 1533 | 0.360 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2009 | 107 | 0.340 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 107 | 0.330 |
Why?
|
| Adenocarcinoma | 6 | 2023 | 7789 | 0.320 |
Why?
|
| Jejunal Diseases | 1 | 2007 | 25 | 0.310 |
Why?
|
| Ileal Neoplasms | 1 | 2007 | 47 | 0.310 |
Why?
|
| Liver Regeneration | 1 | 2008 | 134 | 0.300 |
Why?
|
| Neoplasm Transplantation | 3 | 2021 | 1519 | 0.290 |
Why?
|
| Intestinal Obstruction | 1 | 2007 | 202 | 0.260 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 280 | 0.260 |
Why?
|
| Pancreatitis, Chronic | 2 | 2023 | 116 | 0.260 |
Why?
|
| Prospective Studies | 8 | 2020 | 12873 | 0.240 |
Why?
|
| Colorectal Neoplasms | 6 | 2009 | 3578 | 0.230 |
Why?
|
| Humans | 48 | 2023 | 261506 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 1547 | 0.220 |
Why?
|
| Nitric Oxide | 1 | 2006 | 644 | 0.220 |
Why?
|
| Anastomosis, Surgical | 2 | 2021 | 371 | 0.210 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 702 | 0.210 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2008 | 355 | 0.200 |
Why?
|
| Amylases | 2 | 2019 | 66 | 0.200 |
Why?
|
| Biomedical Technology | 1 | 2021 | 35 | 0.200 |
Why?
|
| ErbB Receptors | 2 | 2019 | 2295 | 0.200 |
Why?
|
| Male | 24 | 2022 | 123000 | 0.190 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 1058 | 0.180 |
Why?
|
| Cell Proliferation | 7 | 2019 | 7226 | 0.180 |
Why?
|
| Retrospective Studies | 11 | 2022 | 37905 | 0.180 |
Why?
|
| Cystadenoma, Serous | 1 | 2019 | 29 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 15862 | 0.180 |
Why?
|
| Margins of Excision | 1 | 2021 | 285 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 4367 | 0.170 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2019 | 95 | 0.170 |
Why?
|
| Preservation, Biological | 1 | 2018 | 15 | 0.170 |
Why?
|
| Heterografts | 1 | 2021 | 733 | 0.170 |
Why?
|
| Semaphorins | 2 | 2016 | 38 | 0.170 |
Why?
|
| Device Removal | 2 | 2018 | 337 | 0.170 |
Why?
|
| Neuropilin-2 | 2 | 2008 | 21 | 0.160 |
Why?
|
| Nutritional Status | 2 | 2019 | 337 | 0.160 |
Why?
|
| RNAi Therapeutics | 1 | 2018 | 42 | 0.160 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 223 | 0.160 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2019 | 161 | 0.160 |
Why?
|
| Laparoscopy | 2 | 2020 | 1225 | 0.160 |
Why?
|
| Clinical Enzyme Tests | 1 | 2018 | 25 | 0.160 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 76 | 0.160 |
Why?
|
| Female | 22 | 2021 | 141928 | 0.160 |
Why?
|
| Pathologists | 1 | 2018 | 91 | 0.160 |
Why?
|
| Liver | 1 | 2008 | 2961 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 2216 | 0.160 |
Why?
|
| Middle Aged | 18 | 2021 | 86204 | 0.150 |
Why?
|
| Quality of Life | 3 | 2023 | 4532 | 0.150 |
Why?
|
| Mesenteric Veins | 1 | 2018 | 73 | 0.150 |
Why?
|
| Aged | 16 | 2021 | 70117 | 0.150 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 38 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2023 | 697 | 0.150 |
Why?
|
| Random Allocation | 2 | 2009 | 703 | 0.150 |
Why?
|
| Radiologists | 1 | 2018 | 163 | 0.150 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 117 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2018 | 299 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 383 | 0.140 |
Why?
|
| Pleural Neoplasms | 1 | 2020 | 470 | 0.140 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2018 | 383 | 0.140 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1016 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 904 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 292 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2016 | 96 | 0.130 |
Why?
|
| Cell Movement | 6 | 2018 | 2466 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 10035 | 0.130 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 138 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4744 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 14889 | 0.120 |
Why?
|
| Organoplatinum Compounds | 2 | 2008 | 702 | 0.120 |
Why?
|
| Transplantation, Heterologous | 3 | 2021 | 1082 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 384 | 0.120 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 85 | 0.120 |
Why?
|
| Mice, Nude | 3 | 2018 | 4307 | 0.120 |
Why?
|
| Malnutrition | 1 | 2017 | 218 | 0.120 |
Why?
|
| Cell Line, Tumor | 8 | 2019 | 14551 | 0.120 |
Why?
|
| Bile | 1 | 2013 | 81 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 45 | 0.110 |
Why?
|
| Risk Factors | 6 | 2021 | 17523 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 830 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2018 | 795 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2018 | 2218 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 1085 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 430 | 0.110 |
Why?
|
| Incidence | 4 | 2019 | 5673 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2594 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2015 | 291 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 2173 | 0.100 |
Why?
|
| Adult | 8 | 2020 | 77950 | 0.100 |
Why?
|
| Surgeons | 1 | 2018 | 519 | 0.100 |
Why?
|
| Erythrocyte Transfusion | 1 | 2013 | 212 | 0.100 |
Why?
|
| Gastroenterology | 1 | 2014 | 195 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2023 | 3341 | 0.100 |
Why?
|
| Length of Stay | 2 | 2018 | 1900 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 5178 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2021 | 6869 | 0.100 |
Why?
|
| Animals | 11 | 2023 | 59536 | 0.100 |
Why?
|
| Mice | 8 | 2023 | 34495 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3821 | 0.100 |
Why?
|
| Treatment Outcome | 9 | 2019 | 32848 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 450 | 0.090 |
Why?
|
| Bevacizumab | 1 | 2013 | 938 | 0.090 |
Why?
|
| Medically Uninsured | 1 | 2010 | 102 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 598 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2019 | 2669 | 0.090 |
Why?
|
| Biomarkers | 2 | 2018 | 5047 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 8865 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 197 | 0.080 |
Why?
|
| Neoplasms | 2 | 2021 | 15193 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 3981 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2013 | 1353 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2013 | 1529 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 347 | 0.070 |
Why?
|
| Remission Induction | 1 | 2013 | 3569 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 14289 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 3552 | 0.070 |
Why?
|
| Jejunum | 1 | 2007 | 216 | 0.070 |
Why?
|
| Constriction, Pathologic | 1 | 2007 | 310 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2017 | 2967 | 0.070 |
Why?
|
| Serotonin | 1 | 2007 | 264 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 13658 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 7551 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 314 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2014 | 1423 | 0.070 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 3842 | 0.070 |
Why?
|
| Registries | 3 | 2019 | 2170 | 0.060 |
Why?
|
| Mesoderm | 1 | 2006 | 404 | 0.060 |
Why?
|
| Epithelium | 1 | 2006 | 720 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 4320 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2023 | 105 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 2314 | 0.060 |
Why?
|
| 5'-Nucleotidase | 1 | 2023 | 61 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 4821 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 600 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 3251 | 0.050 |
Why?
|
| Observer Variation | 1 | 2023 | 671 | 0.050 |
Why?
|
| Common Bile Duct | 1 | 2021 | 27 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2016 | 5270 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2008 | 1011 | 0.050 |
Why?
|
| Prognosis | 2 | 2023 | 21713 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 289 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2992 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2009 | 1443 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 8873 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 1960 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2021 | 185 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 3 | 1 | 2019 | 1 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2021 | 259 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2021 | 445 | 0.040 |
Why?
|
| Parathyroidectomy | 1 | 2021 | 203 | 0.040 |
Why?
|
| Survival Rate | 1 | 2013 | 12221 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3890 | 0.040 |
Why?
|
| Cyst Fluid | 1 | 2019 | 21 | 0.040 |
Why?
|
| Mutation | 2 | 2019 | 15179 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 2021 | 355 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2019 | 222 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 12926 | 0.040 |
Why?
|
| Signal Transduction | 5 | 2019 | 11965 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2019 | 156 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 10001 | 0.040 |
Why?
|
| Cell Survival | 2 | 2019 | 3045 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 2027 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 657 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 4892 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2018 | 218 | 0.040 |
Why?
|
| Cetuximab | 1 | 2019 | 472 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 314 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2021 | 1244 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 348 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2018 | 9180 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 309 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 756 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2018 | 9244 | 0.030 |
Why?
|
| Insulin | 1 | 2021 | 1454 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 2016 | 155 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 460 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 1869 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 575 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 548 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2019 | 1620 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 1382 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 3203 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 4557 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2019 | 2084 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 2231 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 519 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 4975 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1331 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 848 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1987 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1026 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 2864 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1274 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 332 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2013 | 264 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 181 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 1380 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 5395 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2013 | 477 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2018 | 806 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 4971 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 5687 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 1054 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1959 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 4917 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2013 | 451 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2009 | 110 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 6009 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2008 | 10 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2009 | 159 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2008 | 85 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2008 | 30 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2008 | 101 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 44 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2008 | 35 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 4988 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 6089 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 259 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 7222 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 260 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2009 | 249 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2007 | 40 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 4844 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 3472 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 125 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2008 | 348 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 328 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 1154 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 2055 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 591 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 1258 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2006 | 93 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 545 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 886 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 7548 | 0.020 |
Why?
|
| Liposomes | 1 | 2008 | 684 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 650 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2009 | 747 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 451 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2009 | 1944 | 0.020 |
Why?
|
| Apoptosis | 2 | 2009 | 7591 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2330 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2009 | 1385 | 0.010 |
Why?
|
| Cadherins | 1 | 2006 | 660 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 1479 | 0.010 |
Why?
|
| Transfection | 1 | 2008 | 2944 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 3639 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 29902 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 2054 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6207 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 3154 | 0.010 |
Why?
|
| Texas | 1 | 2010 | 6311 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 6150 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2008 | 2819 | 0.010 |
Why?
|
| United States | 1 | 2015 | 15433 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 6295 | 0.010 |
Why?
|
| Child | 1 | 2018 | 29154 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 6682 | 0.010 |
Why?
|
| Carcinoma | 1 | 2008 | 2578 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 5112 | 0.010 |
Why?
|